Clinical trials: Hormone Disturbance
Diabetes Mellitus, Type 2
Targeting the Endothelial Glycocalyx to Enhance Vascular Function and Exercise-Induced Vascular Adaptations in Type 2 Diabetes
The prevalence of type 2 diabetes (T2D) continues to increase in the US, with 26.8 million adults carrying a diagnosis. Importantly, T2D is widespread in the Veteran population.
- Trial name
- NCT05205005
- Testing
- Endocalyx
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- VA Office of Research and Development
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Evaluation of Updated Continuous Glucose Monitoring (CGM) Form Factor in Adults, Adolescents and Pediatrics
The purpose of this study is to demonstrate the performance of the Disposable Sensor (DS5) in subjects age 2 - 80 years, for the span of 170 hours (7 days).
- Trial name
- NCT04436822
- Testing
- Continuous Glucose Monitoring
- Where
- 18 sites in United States, China
- Volunteers
- 317 people
- Sponsor
- Medtronic MiniMed, Inc.
Epithelial Ovarian Cancer, Peritoneal Cancer
Study of Avelumab With or Without Entinostat in Participants With Advanced Epithelial Ovarian Cancer
The purpose of this study is to determine the biologically active dose of entinostat, when given in combination with avelumab, that is safe and warrants further investigation.
- Conditions
- Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- NCT02915523
- Testing
- entinostat, avelumab
- Where
- 12 sites in United States
- Volunteers
- 140 people
- Sponsor
- Syndax Pharmaceuticals
Type 2 Diabetes Mellitus
Efficacy and Safety of Efpeglenatide Versus Dulaglutide in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin
Primary Objective: To demonstrate the non-inferiority of once weekly injection of efpeglenatide in comparison to once weekly injection of dulaglutide on glycated hemoglobin (HbA1c) change in participants with Type 2 diabetes…
- Trial name
- AMPLITUDE-D (NCT03684642)
- Testing
- Efpeglenatide, Dulaglutide, Background therapy Metformin
- Where
- 45 sites in United States, Hungary and 2 more
- Volunteers
- 908 people
- Sponsor
- Sanofi
Type 2 Diabetes Mellitus
Comparison of Vildagliptin vs. Glimepiride on Glucose Variability in Metformin Uncontrolled Type 2 Diabetic Patients
Compare the effect of Vildagliptin plus Metformin versus Glimepiride plus Metformin on glucose variability in T2DM patients.
- Trial name
- VARIABLE (NCT01910441)
- Testing
- Vildagliptin, Glimepiride, Metformin
- Volunteers
- 95 people
- Sponsor
- Novartis Pharmaceuticals
Diabetes Type 1
CGM Precision and Glycaemic Variability
Use of devices for continuous monitoring of the blood sugar is valuable for people with diabetes to understand their disease and to help prevent low blood sugar.
- Trial name
- NCT03842683
- Testing
- CGM
- Volunteers
- 472 people
- Sponsor
- Peter Vestergaard
Diabetes Mellitus, Type 2
Lispro Mid Mixture (MM) Intensive Mixture Therapy With Progressive Dose-Titration of Lispro Low Mixture (LM) or Biphasic Insulin Aspart 30/70 (S019)
Investigation into patients with type 2 diabetes mellitus not achieving adequate glycemic control while treated with combination of premixed insulin analogue formulations twice daily and metformin will be randomly assigned to…
- Trial name
- S019 (NCT00393705)
- Testing
- Insulin Biphasic Aspart 30/70, insulin lispro LM, insulin lispro MM
- Where
- 9 sites in Croatia, Poland and 3 more
- Volunteers
- 302 people
- Sponsor
- Eli Lilly and Company
Ovarian Neoplasm
Study to Evaluate the Safety and Efficacy of TSR-042, Bevacizumab, and Niraparib in Participants With Recurrent Ovarian Cancer
The primary objective of this sub study is to evaluate the efficacy of the combination of TSR-042, bevacizumab, and niraparib in participants with advanced, relapsed, high-grade ovarian, fallopian tube, or primary peritoneal…
- Trial name
- COHORT-A (NCT05751629)
- Testing
- Dostarlimab, Bevacizumab, Niraparib
- Where
- 10 sites in United States
- Volunteers
- 41 people
- Sponsor
- Tesaro, Inc.
Diabetic Retinopathy
A Multi-center Study to Evaluate Performance of an Automated Device for the Detection of Diabetic Retinopathy
Diabetes affects 30.3 million people or 9.3% of the population of the United States. Results of a study by the Eye Diseases Prevalence Research Group reveal that 40% of diabetes patients have some degree of diabetic retinopathy…
- Trial name
- NCT02963441
- Testing
- LumineticsCore (formerly IDX-DR)
- Volunteers
- 900 people
- Sponsor
- Digital Diagnostics, Inc.
Diabetes Mellitus, Type 2
A Study in Participants With Type 2 Diabetes Mellitus (AWARD-2)
The purpose of this study is to determine if LY2189265 is effective in reducing hemoglobin A1c (HbA1c) and safe, as compared to Insulin Glargine in participants with Type 2 Diabetes.
- Trial name
- AWARD-2 (NCT01075282)
- Testing
- Insulin Glargine, LY2189265, Metformin
- Where
- 78 sites in Argentina, Australia and 18 more
- Volunteers
- 810 people
- Sponsor
- Eli Lilly and Company
Type 1 Diabetes Mellitus
Steroid-free and Long-term Calcineurin-free Trial in Islet Cell Transplantation
The purposes of this study are: 1. To reverse hyperglycemia and insulin dependency in patients with type 1 diabetes mellitus through islet transplantation utilizing steroid free, calcineurin-inhibitor free immunosuppression. 2.
- Trial name
- NCT00315627
- Testing
- Islet transplantation
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Rodolfo Alejandro
Diabetes Mellitus, Type 2
Long-term Study of Nateglinide+Valsartan to Prevent or Delay Type II Diabetes Mellitus and Cardiovascular Complications
This study is a test of the safety and effectiveness of two drugs, one for diabetes and one for hypertension, in keeping patients with high lab values of glucose from progressing to frank diabetes and developing cardiovascular…
- Trial name
- Navigator (NCT00097786)
- Testing
- Valsartan 160 mg + nateglinide 60 mg
- Where
- 38 sites in United States, Argentina and 36 more
- Volunteers
- 9,306 people
- Sponsor
- Novartis Pharmaceuticals
Hypertension
Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes Mellitus
The purpose of the study was to evaluate the blood pressure (BP)-lowering efficacy of the combination of aliskiren and valsartan, as initial therapy, compared to valsartan monotherapy in Type II Diabetic patients with Stage II…
- Trial name
- ViVID (NCT00927394)
- Testing
- Aliskiren, Valsartan
- Where
- 4 sites in United States
- Volunteers
- 1,143 people
- Sponsor
- Novartis
Fallopian Tube Cancer, Ovarian Cancer
S9912 Combination Chemo in Stage III Ovarian Cancer,
RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer
- Trial name
- NCT00003896
- Testing
- cisplatin, liposomal doxorubicin, paclitaxel
- Where
- 104 sites in United States
- Volunteers
- 68 people
- Sponsor
- SWOG Cancer Research Network
Type 2 Diabetes Mellitus
An Administration Method Study of Human Regular U-500 Insulin (LY041001) in Participants With Type 2 Diabetes Mellitus
The main purpose of this study is to evaluate the efficacy and safety of the study drug known as human regular U-500 insulin (U-500R) administered by continuous subcutaneous insulin infusion (CSII) versus multiple daily…
- Trial name
- VIVID (NCT02561078)
- Testing
- Human regular U-500 insulin (CSII), Human regular U-500 insulin (MDI)
- Where
- 57 sites in United States, Puerto Rico
- Volunteers
- 420 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus
Advancing Insulin Prescribing in General Practice
Family Physicians, the subjects of this trial are reluctant to initiate insulin in patients with type 2 diabetes due to a lack of familiarity and comfort with this clinical strategy.
- Trial name
- AIM@GP (NCT00593489)
- Testing
- Basal Insulin Initiation Strategy
- Where
- Canada
- Volunteers
- 154 people, healthy volunteers welcome
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Mesothelioma, Mesotheliomas Pleural
A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
TC-510 is a novel cell therapy that consists of autologous genetically engineered T cells expressing two synthetic constructs: first, a single-domain antibody that recognizes human Mesothelin, fused to the CD3-epsilon subunit…
- Conditions
- Mesothelioma, Mesotheliomas Pleural, Mesothelioma, Malignant, Mesothelioma Peritoneum
- Trial name
- NCT05451849
- Testing
- TC-510, Fludarabine, Cyclophosphamide
- Where
- 7 sites in United States
- Volunteers
- 14 people
- Sponsor
- TCR2 Therapeutics
Obesity, Cardiovascular Disease
IMPACT: Inactivity Monitoring and Physical Activity Controlled Trial
As individuals age, their physical activity decreases and sedentary time increases. Even small changes in these two behaviors can greatly decrease risks for several major health problems, including cardiovascular disease…
- Conditions
- Obesity, Cardiovascular Disease, Cancer, Diabetes
- Trial name
- IMPACT (NCT01869348)
- Testing
- Monitor intervention
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- The University of Texas Medical Branch, Galveston
Diabetes
Patient Specific 3D Printed Diabetic Insoles to Reduce Plantar Pressure
In this research study, the investigators are evaluating if novel custom foot orthotics improves foot health and mobility for people who are at increased risk of developing foot ulcers.
- Trial name
- 3D Insole (NCT05301478)
- Testing
- standard of care insole, 3D Printed Insole - pressure based, 3D Printed Insole - FEA
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- VA Office of Research and Development
Pancreatic Cancer, Pancreas Neoplasms
Human Leukocyte Antigen-A*02:01-restricted Tumor Vessel Specific Peptide Vaccination for Advanced Pancreatic Cancer
Pancreatic cancer is the fourth leading cause of cancer death in the United States, and no combination therapy is far superior to gemcitabine alone.
- Trial name
- NCT00683085
- Testing
- HLA-A*02:01-restricted VEGFR1-derived peptide vaccination
- Where
- Japan
- Volunteers
- 2 people
- Sponsor
- Tokyo University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.